

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7045557
<b>Application Number:</b>	09830992
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7169
<b>Title of Invention:</b>	Substituted 2-phenylbenzimidazoles, the production thereof and their use
<b>First Named Inventor/Applicant Name:</b>	Wilfried Lubisch
<b>Customer Number:</b>	32116
<b>Filer:</b>	Susan Lynne Steele/Melissa Solis
<b>Filer Authorized By:</b>	Susan Lynne Steele
<b>Attorney Docket Number:</b>	49500
<b>Receipt Date:</b>	19-FEB-2010
<b>Filing Date:</b>	03-MAY-2001
<b>Time Stamp:</b>	12:33:55
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810
RAM confirmation Number	10941
Deposit Account	010025
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	0050-049500USO1_SB30_RCE_2-19-2010.pdf	697396 1df92a0b12a3b40303772dde1a1fe25c64f9a805	no	3
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Filed (SB/08)	0050-049500USO1_SB08a_IDS_Form_2010.pdf	614204 adec6859b835a2eb4b09357134f3b8d32559ffc6	no	7
Warnings:					
Information:					
3	Foreign Reference	DE3830060A1translation.pdf	771042 41cacc51b970bbe4c7835de0a25e168532ff92d	no	24
Warnings:					
Information:					
4	Foreign Reference	DE19916460B4translation.pdf	2122806 14a4a90d0fe115d2268198f98051b9bf08137d0c	no	65
Warnings:					
Information:					
5	Foreign Reference	WO2000068206A1_19920936.pdf	2901197 5b4d5147040918fa4ce1cca1264a115f615a9c5b	no	70
Warnings:					
Information:					
6	Foreign Reference	WO2001082877A2_10021468.pdf	3832220 38c0907e781bc5012aa75b1f57fb57266f39880	no	92
Warnings:					
Information:					
7	Foreign Reference	GB1354554.pdf	300861 f3f8aa3ed16b034e5cfb0a8b7a0400c66b7e4b42	no	6
Warnings:					
Information:					
8	Foreign Reference	WO199704771A1.pdf	2571377 0a8dda9b5947d02215a63d910c00d5d034f499af	no	66

Warnings:					
Information:					
9	Foreign Reference	WO1998039343A1.pdf	17311123	no	378
			934ddc4c017b3dc331a66db8aa3972dd52ab90b4		
Warnings:					
Information:					
10	Foreign Reference	WO2000026192A1.pdf	3064958	no	75
			7acb7072796ac5b84d93eb078c1f671ee3d44b17		
Warnings:					
Information:					
11	Foreign Reference	WO2000029384A1.pdf	1439975	no	33
			40e0469c93d073a85a1f76cdb44ee29603fa91a4		
Warnings:					
Information:					
12	Foreign Reference	WO2000032579A1.pdf	2008134	no	44
			3e83a4372d1bfd0f2c8c22ae1d636d8504ba68d4		
Warnings:					
Information:					
13	Foreign Reference	WO200121615A1translation.pdf	2326260	no	98
			ccb9bda7c57359ba825d08f8cc57c084e8b7b2c4		
Warnings:					
Information:					
14	Foreign Reference	WO2001021634A1.pdf	4463221	no	135
			6ad27f2d61d6d67c25622f00f21a369d60de79e2		
Warnings:					
Information:					
15	Foreign Reference	WO2001082877A2.pdf	3832220	no	92
			c001ecf0b65dc2edd8c1a6e6418680aa4f7f8482		
Warnings:					
Information:					
16	NPL Documents	GilchristJournaloftheChemicalsocietyPerlomTrans.pdf	508843	no	6
			93b732c190ad667a55df5ef941f2314255375b5d		
Warnings:					
Information:					
17	NPL Documents	GriffinPharmaceuticalSciences.pdf	350031	no	5
			8664ef8a10a946ba5f3195c969319996b14edb8b		

Warnings:					
Information:					
18	NPL Documents	Kroger_et_al_Inflammation_2023-215_1996.pdf	596447	no	13
			c205038810c2c652ac0bbf93fd1a47908b3288d1		
Warnings:					
Information:					
19	NPL Documents	Burkart_et_al_Nature_Medicine_5_3_314-319_1999.pdf	2098039	no	6
			7f7fed06cda42f9f6a82ed97c077b94a290b1631		
Warnings:					
Information:					
20	NPL Documents	Chen_et_al_Cancer_Chemotherapy_Pharmacology_22_303-307_1988.pdf	427772	no	5
			4007c0c97c55e818795833e0d62ac4821f62ce0c		
Warnings:					
Information:					
21	NPL Documents	Cuzzocrea_et_al_Eur_J_Pharmacol_342_67-76_1998.pdf	899077	no	10
			8e0cefe404d691bd51d58c9236bf86fbdcc051		
Warnings:					
Information:					
22	NPL Documents	Ehrlich_et_al-Rheumatol_Int_15_171-172_1995.pdf	197879	no	2
			8c9ebac21b9bcd1b49dd51ba97b70c495f48e634b		
Warnings:					
Information:					
23	NPL Documents	Szabo_et_al_Proc_Natl_Acad_Sci_USA_95_7_3867-3872_1998.pdf	321605	no	6
			782bfa20941ee50c13154c155b02d3797c3aaa0		
Warnings:					
Information:					
24	NPL Documents	Thiemermann_et_al_PNAS_94_679-683_1997.pdf	246193	no	5
			dc83fae7bb268a5870d8540af3ea460c8a4dd9a5e		
Warnings:					
Information:					
25	NPL Documents	Weltin_et_al_Int_J_Immunopharmacol_17_4_265-271_1995.pdf	423655	no	7
			db941f269fc9fcd138a5d627f8625f669983898b		
Warnings:					
Information:					
26	NPL Documents	WhiteBioorganicMedicinalChemistryLetters.pdf	274552	no	5
			d96f218868bd1996a57ca2f73ade529cd5c925d4		

<b>Warnings:</b>					
<b>Information:</b>					
27	Fee Worksheet (PTO-875)	fee-info.pdf	29932	no	2
			bed9ac2a2c077789ff36c75ddea059766d2f624e		
<b>Warnings:</b>					
<b>Information:</b>					
Total Files Size (in bytes):				54631019	
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  <b>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</b></p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  <b>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</b></p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  <b>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</b></p>					